Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Eureka Therapeutics Inc patents


Recent patent applications related to Eureka Therapeutics Inc. Eureka Therapeutics Inc is listed as an Agent/Assignee. Note: Eureka Therapeutics Inc may have other listings under different names/spellings. We're not affiliated with Eureka Therapeutics Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "E" | Eureka Therapeutics Inc-related inventors


Constructs targeting afp peptide/mhc complexes and uses thereof

The present application provides constructs comprising an antibody moiety that specifically binds to a complex comprising an afp peptide and an mhc class i protein. Also provided are methods of making and using these constructs.. ... Eureka Therapeutics Inc

T cell receptor-like antibodies specific for a prame peptide

The presently disclosed subject matter provides antigen-binding proteins that specifically bind to preferentially expressed antigen of melanoma (prame), including humanized, chimeric and fully human antibodies against prame, antibody fragments (e.g., scfv, fab and f(ab)2), chimeric antigen receptors (cars), fusion proteins, and conjugates thereof. The antigen-binding proteins and antibodies bind to a prame peptide/hla class i molecule complex. ... Eureka Therapeutics Inc

Anti-ror1 chimeric antigen receptors

The invention provides improved compositions for adoptive cell therapies for cancers that express ror1.. . ... Eureka Therapeutics Inc

Anti-ror1 antibodies

The invention relates to antibodies, and in particular, to antibodies exhibiting specificity for receptor tyrosine kinase-like orphan receptors (ror), and to uses thereof, for example in the treatment of cancer. The invention extends to polynucleotide and polypeptide sequences encoding the antibodies, and therapeutic uses thereof, and to diagnostic kits comprising these molecules. ... Eureka Therapeutics Inc

Monoclonal antigen-binding proteins to intracellular oncogene products

Antigen binding proteins specific for an hla-a2 restricted ras peptide are disclosed. The antigen binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, fab fragments, f(ab′)2 fragments, and single chain fv fragments. ... Eureka Therapeutics Inc

Antibody agents specific for human cd19 and uses thereof

Described herein are human antibody agents and multi-specific binding agents that specifically bind human cd 19, in particular, native human cd 19. Also provided herein are methods of using the same or compositions thereof for the detection, prevention and/or therapeutic treatment of diseases characterized by cd 19 expression, in particular, b cell lymphomas and leukemias.. ... Eureka Therapeutics Inc

Novel pd-1 immune modulating agents

The present application provides anti-pd-1 antigen-binding proteins or a fragment thereof, as well as nucleic acids encoding anti-pd-1 antigen-binding proteins or car t cells expressing such antigen-binding protein or fragment. Also provided are methods of regulating t cells or treating patients using such constructs or cells.. ... Eureka Therapeutics Inc

Antibodies targeting b-cell maturation antigen and methods of use

The presently disclosed subject matter provides antibodies that bind to b-cell maturation antigen (bcma) and methods of using the same.. . ... Eureka Therapeutics Inc

Antibodies targeting g-protein coupled receptor and methods of use

The presently disclosed subject matter provides antibodies that bind to gprc5d and methods of using the same.. . ... Eureka Therapeutics Inc

Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof

The presently disclosed subject matter provides for methods and compositions for treating multiple myeloma. It relates to chimeric antigen receptors (cars) that specifically target a g-protein coupled receptor (e.g., a g-protein coupled receptor family c group 5 member d (gprc5d)), and immunoresponsive cells comprising such cars. ... Eureka Therapeutics Inc

Antibody/t-cell receptor chimeric constructs and uses thereof

The present application provides antibody-tcr chimeric constructs comprising an antibody moiety that specifically binds to a target antigen fused to a tcrm capable of recruiting at least one tcr-associated signaling module. Also provided are methods of making and using these constructs.. ... Eureka Therapeutics Inc

Constructs targeting afp peptide/mhc complexes and uses thereof

The present application provides constructs comprising an antibody moiety that specifically binds to a complex comprising an afp peptide and an mhc class i protein. Also provided are methods of making and using these constructs.. ... Eureka Therapeutics Inc

Anti-ror1 antibodies

The invention relates to antibodies, and in particular, to antibodies exhibiting specificity for receptor tyrosine kinase-like orphan receptors (ror), and to uses thereof, for example in the treatment of cancer. The invention extends to polynucleotide and polypeptide sequences encoding the antibodies, and therapeutic uses thereof, and to diagnostic kits comprising these molecules. ... Eureka Therapeutics Inc

Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof

The presently disclosed subject matter provides for methods and compositions for treating a neoplasia (e.g., multiple myeloma). It relates to chimeric antigen receptors (cars) that specifically target fc receptor-like 5 (fcrl5), e.g., domain 9 of fcrl5, and immunoresponsive cells comprising such cars. ... Eureka Therapeutics Inc

03/30/17 / #20170088630

T cell receptor-like antibodies specific for a wti peptide presented by hla-a2

The present invention provides antigen binding proteins that specifically bind to wilms' tumor protein (wt1), including humanized, chimeric and fully human antibodies against wt1, antibody fragments, chimeric antigen receptors (cars), fusion proteins, and conjugates thereof. The antigen binding proteins and antibodies bind to hla-a0201-restricted wt1 peptide. ... Eureka Therapeutics Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Eureka Therapeutics Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Eureka Therapeutics Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###